Format

Send to

Choose Destination
Neuropsychopharmacology. 2017 Oct;42(11):2105-2113. doi: 10.1038/npp.2017.84. Epub 2017 Apr 26.

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Author information

1
Psychedelic Research Group, Centre for Psychiatry, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
2
University of Oxford Department of Psychiatry and Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Abstract

Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.

PMID:
28443617
PMCID:
PMC5603818
DOI:
10.1038/npp.2017.84
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center